compound introduction
BIO5192 hydrate is a selective and potent integrin α4β1 (VLA-4) inhibitor ( K d IC50& Target:α4β1 1.8 nM (IC 50 ) α9β1 138 nM (IC 50 ) α2β1 1053 nM (IC 50 ) α4β7 >500 nM (IC 50 ) In Vivo:The combination of BIO5192 hydrate (1mg/kg; i.v.) and Plerixafor (5mg/kg; s.c.) exert an additive effect on progenitor mobilization. BIO5192 hydrate (30mg/kg; s.c; bid; during days 5 through 14) delays paralysis associated with EAE (experimental a Biological Activity:BIO5192 hydrate is a selective and potent integrin α4β1 (VLA-4) inhibitor ( K d
